Celularity Receives Notice from Nasdaq on Fee Payment Issues
Celularity Inc. (Nasdaq: CELU), a leader in cellular and regenerative medicine, has received a notification from Nasdaq concerning an outstanding fee related to its listing on the stock exchange. This notice, which brings attention to the company's non-payment of required fees, places the future of its continued listing in jeopardy unless an appeal is filed. The company has accrued a past due fee amounting to $70,000, which it has since settled as of April 25, ensuring compliance with Nasdaq’s financial obligations.
Delinquency in Filing Form 10-K
In addition to the unpaid fees, Nasdaq informed Celularity of a delinquency regarding its Form 10-K filing for the year ending December 31. This lapse not only raises compliance issues but also establishes a separate ground for possible delisting under Nasdaq Listing Rule 5250(c)(1). To remedy this situation, the company has been directed to submit a comprehensive plan of compliance. In the event that Celularity opts not to appeal Nasdaq's decision, it must prepare for a suspension of trading for its common stock starting on May 1.
Future Steps for Celularity
The company is acting swiftly to rectify its reporting issues, focusing on submitting its overdue Form 10-K as part of their proactive strategy. Celularity’s management expresses optimism about resolving these matters shortly, emphasizing a commitment to maintaining transparency and regulatory compliance.
Understanding Celularity's Mission and Services
Celularity Inc. is notably distinguished in the field of regenerative medicine, concentrating on the development and commercialization of groundbreaking biomaterial products and innovative cell therapies. Their approach harnesses the biological capabilities of the placenta, from which they derive their allogeneic, cryopreserved cell therapies. By leveraging the unique properties of placental materials, Celularity aims to create effective, accessible, and economical treatment alternatives to address various unmet healthcare needs worldwide.
Impact of Nasdaq’s Notification on Celularity
The implications of Nasdaq's notification are significant for Celularity, not just for its current operational status, but also for its market reputation and investor confidence. Being listed on Nasdaq symbolizes credibility in the financial markets, and compliance with listing rules is crucial for the company's ongoing growth and investment opportunities.
Company's Commitment to Compliance
In response to this notice, Celularity is focused on fulfilling its compliance obligations, demonstrating their commitment to uphold the standards set by Nasdaq. The company is emphasizing internal measures to ensure timely filings and management of finances, thereby safeguarding its market presence.
Frequently Asked Questions
What led to the Nasdaq notice for Celularity?
Celularity received a notice due to non-payment of fees and a delinquency in filing their Form 10-K, which are essential for maintaining their listing.
How much does Celularity owe Nasdaq?
The company had a past due fee amounting to $70,000, which was paid in full on April 25.
What are the consequences if Celularity does not appeal?
If Celularity chooses not to appeal the notice, trading of its common stock will be suspended starting May 1.
What actions is Celularity taking to remain compliant?
Celularity is actively working to file its overdue Form 10-K and is developing a compliance plan to address Nasdaq's concerns.
Why is Celularity important in regenerative medicine?
Celularity is pioneering advanced treatments derived from placental cells, aiming to meet significant health needs through innovative therapies.
